On February 9, Sansure Bio released an announcement on the appointment of senior management personnel.

According to the company's business development needs, the board of directors agreed to appoint Mr. Yin Peng as the deputy general manager of the company (resume attached) for a term from the date of consideration and approval at the second interim meeting of the second session of the board of directors of the company in 2023 to the date of expiration of the current term of the board of directors, after review by the nomination committee of the board of directors.

Attachment: Senior Management Biographies

Peng Yin, male, born in December 1964, is an American citizen with a Ph. From March 1998 to June 2000, he was a postdoctoral fellow at Harvard Medical School; from July 2000 to August 2004, he was a senior scientist at Zycos, Inc. in Boston, USA; from September 2004 to April 2022, he was the Head of Asia-Pacific R&D Center at Abbott Diagnostics, the Founder and Head of Abbott Diagnostics China R&D Center, and the Director of Global Scientific and Medical Affairs at Abbott Diagnostics. From April 2022 to December 2022, he served as co-CEO of Baotai Biologics in Xiamen, China; in December 2022, he joined  Sansure Biotech and is currently the Chief Technology Officer of Sansure Biotech.

Mr. Yin Peng does not hold any shares of the Company and has no relationship with the controlling shareholder, the de facto controller, shareholders holding more than 5% of the shares and other directors, supervisors and senior management of the Company; he is not prohibited from acting as a director, supervisor or senior management of the Company as stipulated in the Company Law of the People's Republic of China; he has not been prohibited from entering the securities market by the CSRC; he has not been publicly recognized by the stock exchange as unsuitable to act as a director, supervisor or senior management of a listed company; he has not been subject to administrative punishment by the CSRC and public condemnation or notification of criticism by the CSRC for suspected crimes or suspected violations of law. He is not suitable to be a director, supervisor or senior management of a listed company; has not been subject to administrative punishment by CSRC and public reprimand or notification of criticism by the stock exchange; has not been investigated by judicial organs for suspected crimes or investigated by CSRC for suspected violations of law; and is not a "defaulted executee" after investigation.